首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Formulation and In Vitro Evaluation of Sustained Release Floating Matrix Tablet of Levofloxacin by Direct Compression Method
【24h】

Formulation and In Vitro Evaluation of Sustained Release Floating Matrix Tablet of Levofloxacin by Direct Compression Method

机译:直接压缩法制备左氧氟沙星持续释放浮体的配制和体外评价

获取原文
           

摘要

The objective of the present work was to develop Gastro retentive dosage forms which would remain in the stomach and upper part or GIT for a prolonged period of time thereby maximizing the drug release at desired site within the time before GRDFs left the stomach and upper part of the GIT, has provoked a great deal of increased interest in the formulation of such drug as floating drug delivery systems. Levofloxacin, (BCS class I) is a fluoroquinolone anti-bacterial agent. The rationale for the formulation of floating matrix tablet are acidic solubility of levofloxacin, residence of Halicobactor pylori mainly in sub region of stomach and the overdosing associated adverse effect due to continuous intake of drug in acute infection. A simple visible spectrophotometric method was employed for the estimation of levofloxacin at 294 nm and Beer’s law is obeyed in the concentration range of 2-10 μg /ml. Floating matrix tablet of levofloxacin was prepared by direct compression method using different polymers like hydroxyl propyl methyl cellulose (HPMC K4) and carbopol 934 as matrix formation polymers, sodium bicarbonate and citric acid was used as gas generating agents. The FTIR spectra of the levofloxacin and other excipients alone and in combination show the compatibility of the drug and excipients. Six formulations of different polymer percentages were formulated (F1-F6). Pre-compression parameters were evaluated. The influence of matrix forming agents and binary mixtures of them on levofloxacin release was investigated. The formulated tablets were characterized by hardness, friability, thickness, weight variation and in vitro drug release. The formulated tablets had acceptable physicochemical characters. The data obtained from the in-vitro dissolution studies of optimized batch F4were fitted in different models. The optimized formulation F4 showed 99.25% drug content and swelling index of 79.85 %. Drug release mechanism was found to be first order kinetics. Levofloxacin floating tablets exhibited increased gastric residence time, there by improved bioavailability and therapeutic effect of the drug.
机译:本作本作的目的是开发胃固定剂型,其将在胃和上部或Git延长一段时间内,从而在GRDF留下胃和上部的时间内最大化所需部位的药物释放。 Git,引起了对这种药物的制剂的兴趣增加了很大的兴趣,作为浮动药物递送系统。左氧氟沙星(BCS Accus I)是氟代喹啉抗菌剂。浮动基质的制剂的基本原理是左氧氟沙星的酸性溶解度,Halicobactor Pylori的住宿主要是胃部亚区域和过量的急性感染中药物的过量的药物过量的不良反应。使用简单的可见分光光度法,用于估计左氧氟沙嘧啶,在294nm,啤酒定律在2-10μg/ ml的浓度范围内进行。通过使用不同聚合物如羟基丙基甲基纤维素(HPMC K4)和Carbopol 934,如基质形成聚合物,用碳酸氢钠和柠檬酸,通过直接压制法制备左氧化物的浮动基质片,用作气体发生剂。单独的左氧氟沙星的FTIR光谱和其他赋形剂和组合表明药物和赋形剂的相容性。配制六种不同的聚合物百分比的制剂(F1-F6)。评估预压缩参数。研究了基质形成剂和二元混合物对左氧氟沙星释放的影响。配制片剂的特征在于硬度,脆性,厚度,重量变异和体外药物释放。配制的片剂具有可接受的物理化学特性。从不同型号的优化批量F4的体外溶解研究中获得的数据。优化的配方F4显示出99.25%的药物含量和79.85%的溶胀指数。发现药物释放机制是第一阶动力学。通过改善药物的生物利用度和治疗效果,左氧氟沙星浮动片剂表现出增加的胃停留时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号